8-K current report · filed Jul 16, 2026

CATALYST PHARMACEUTICALS, INC. (CPRX) 8-K Current Report: July 16, 2026

Item 5.02Item 5.03Item 3.01Item 2.01Item 3.03Item 5.01CPRX overview

Short answer

CATALYST PHARMACEUTICALS, INC. (CPRX) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item 3.01 (Notice of Delisting), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant). Item 2.01 contains no substantive acquisition or disposition details.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

CATALYST PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Item 2.01 contains no substantive acquisition or disposition details
  • Investors should review the referenced Introductory Note and Items 3.01, 3.03, 5.01, 5.02 and 5.03 for transaction implications

Item 3.01 · Notice of Delisting

  • Nasdaq delisting follows completion of the July 14, 2026 merger, materially changing shareholder liquidity and trading access
  • Trading suspension continued through July 15, 2026, with Nasdaq suspension effective July 16, 2026
  • Form 25 filing initiates removal from Nasdaq and deregistration under Exchange Act Section 12(b)
  • Planned Form 15 filing would terminate Section 12(g) registration and suspend SEC reporting obligations under Sections 13 and 15(d)

Item 3.03 · Material Modification to Rights of Security Holders

  • Merger converted each outstanding CPRX share into the right to receive merger consideration
  • Former shareholders lost voting and other equity rights at the merger effective time
  • Merger consideration subject to applicable tax withholdings and payable without interest
  • Investor outcome depends on merger consideration terms referenced in the Introductory Note and Merger Agreement

Item 5.01 · Changes in Control of Registrant

  • Merger completion transferred control of Catalyst Pharmaceuticals to Parent
  • Catalyst became a wholly owned subsidiary, ending its independent public-company status
  • No known arrangements indicate another change in control is expected

Item 5.02 · Departure/Election of Directors or Officers

  • All seven pre-merger directors resigned at the merger’s effective time
  • Departures unrelated to disagreements over operations, policies, or practices
  • Sergio Marullo di Condojanni, Massimo Marin, and Enrica Dogali became directors of the surviving corporation
  • Complete board turnover signals post-merger governance and strategic-control transition

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • Certificate of incorporation and bylaws replaced in full at merger effective time
  • Amendments align governance documents with Merger Sub and the surviving corporation
  • Exhibit 3.1 contains the amended certificate; Exhibit 3.2 contains amended bylaws

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other CATALYST PHARMACEUTICALS, INC. 8-K filings

Get the next CPRX 8-K as it lands

Follow CPRX for push alerts, or ask the research agent what this filing means.